Incyte Q2 Results Confirm CMS Boost, but Demand Acceleration Still Elusive

What happened

Incyte’s Q2 2026 results included a $246 million CMS accrual reversal that lifted Opzelura net sales, yet underlying U.S. prescription growth held near 17% year-over-year. Total revenue benefited from the one-time gain, while Jakafi still generated over 60% of product sales, underscoring continued franchise concentration. Management raised full-year Opzelura guidance, but the increase largely reflected the non-cash reversal rather than a step-up in demand. The market’s positive reaction likely stems from the final resolution of the line-extension dispute rather than evidence of accelerating fundamentals. Investors now need to watch whether Opzelura can sustain above-20% net sales growth once the reversal laps, with EU atopic dermatitis approval the next major catalyst.

Implication

While the CMS reversal and EU approval path improve the near-term picture, Incyte still needs to demonstrate that Opzelura growth is driven by higher prescription volumes rather than accounting relief. The next two quarters will be critical to see if U.S. TRx growth accelerates beyond its 17% trend and if ex-U.S. sales begin to ramp meaningfully. Until then, the stock’s current valuation already prices in much of the good news, and the risk of a rerating lower remains if diversification fails to materialize. Maintaining a WAIT rating with a preference for adding on pullbacks below $105.

Thesis delta

The CMS settlement and CHMP opinion were already incorporated into our WAIT rating; Q2 results confirm the reversal but do not alter the core thesis that sustainable value creation hinges on organic demand growth for Opzelura and the non-Jakafi portfolio. The investment case remains contingent on Q3 and beyond showing evidence that revenue growth is increasingly volume-driven.